New research identifies biological differences in pancreatic cancer

by Tim Tedeschi, University of Cincinnati

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

New research from the University of Cincinnati Cancer Center found biological differences in pancreatic cancer tumors and immune environments, opening the possibility for more personalized treatments for different populations.

Led by Nina Steele, Ph.D., assistant professor in UC's College of Medicine, in collaboration with Howard Crawford, Ph.D., scientific director of the Henry Ford + Michigan State University Pancreatic Cancer Center, the research was recently published in the journal Cancer Research.

Incidence and survival rates of pancreatic cancer vary between different populations of Americans, but sufficient data did not previously exist to determine specific genomic differences between populations.

"We didn't have an accurate reflection of all of the patients impacted by the disease reflected in the data," said Steele, who is also a Cancer Center member. "There had never been a large-scale multiomic effort looking at tens of thousands of biological markers across a diverse cohort of pancreatic cancer patients."

Steele and her colleagues at Henry Ford Health (where she started the project) and UC mapped out the genomic information of a representative sample of the American population diagnosed with pancreatic cancer.

Pancreatic cancer is 20% more likely to develop in Black African Americans (BAA), and the team found the cancer cells of BAA and non-African Americans (NAA) had different molecular signatures.

"The cancer cells make unique RNAs and proteins, so that could be relevant to how individual patients from different groups could respond to targeted therapies like RAS inhibitors," Steele said. "The markers upregulated in Black patients likely represent a type of cells typically associated with drug resistance, so this biological difference could play a role in outcomes."

Additionally, immune cells called B cells within pancreatic tumor microenvironments are different between BAA and NAA populations, with the B cells within BAA samples found to be more abundant but also more immunosuppressive (dampening the body's natural immune response to fight the cancer).

"This may mean the B cells are helping the cancer cells hide in this patient population," Steele said. "This could help explain why this population is more likely to get the cancer, and why it's worse when they get it, but more work is needed on pancreas tissues from individuals that do not have cancer."

Steele said the study provides a framework for further research into the mechanisms behind these biological differences across populations and how the differences affect outcomes.

The research is part of a larger trend of personalized medicine, with more detailed data leading to specific treatments to meet the individual needs of patients. Further research could even potentially lead to the classification of entirely new subtypes of pancreatic cancer, similar to what has occurred in breast and prostate cancer.

"The Cancer Center is here to serve everybody, and to find the answers that help all patients," Steele said. "The hope is to know more about the characteristics of the cancer cells earlier on, so that we have a plan of attack for what therapies come after current standards of care in a very rational way. We're headed toward forecasting, the ability to better predict what will happen to every patient in their journey before it happens."

Publication details

Yuesong Wu et al., Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments, Cancer Research (2026). DOI: 10.1158/0008-5472.can-25-2748

Journal information: Cancer Research

Key medical concepts

Pancreatic CancerB-Lymphocytes

Clinical categories

OncologyClinical genetics Provided by University of Cincinnati Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: New research identifies biological differences in pancreatic cancer (2026, November 6) retrieved 7 November 2026 from https://medicalxpress.com/news/2026-11-biological-differences-pancreatic-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.